Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy.
OBJECTIVE
Gastric cancer is a virulent disease with a poor prognosis despite multidisciplinary treatment. The present study was designed to clarify the clinical effects of chemoimmunotherapy for patients with advanced gastric cancer.


METHODS
The enrolled gastric cancer patients had distant metastases including liver (n = 2) and peritoneal dissemination (n = 21). The patients had received the chemotherapy according to the results of chemosensitivity test and adoptive immunotherapy by activated killer cells.


RESULTS
There were no severe toxicities, except fever and mild myelo-suppression. Four patients had complete response (17.4%) and 10 patients had partial response (43.5%). The performance status was improved in responders (p < 0.01, from 2.6 +/- 0.5 to 1.4 +/- 0.7); however, this was not changed in non-responders (from 2.2 +/- 0.9 to 2.0 +/- 1.2). The survival of responders was longer than that of non-responders (p < 0.05, 198 +/- 69 days vs. 104 +/- 68 days).


CONCLUSIONS
It was clarified that responders by chemoimmunotherapy had a good quality of life and longer survival.
Yamaue
H
H
Second Department of Surgery, Wakayama Medical School, Japan. yamaue-h@wakayama-med.ac.jp
Tanimura
H
H
Mizobata
S
S
Noguchi
K
K
Tani
M
M
Tsunoda
T
T
Iwahashi
M
M
Nakamori
M
M
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome